Curated News
By: NewsRamp Editorial Staff
February 05, 2026

TransCode Submits IND Amendment for Phase 2a Cancer Trial Targeting Metastasis

Discuss on Substack
Original Source

TLDR

  • TransCode Therapeutics gains a potential edge with its IND amendment for TTX-MC138, targeting colorectal cancer recurrence to capture market share in oncology.
  • TransCode's Phase 2a trial will enroll 45 ctDNA-positive colorectal cancer patients starting in 2026, testing TTX-MC138's effect on minimal residual disease.
  • This trial offers hope for colorectal cancer patients by aiming to prevent recurrence, potentially improving survival and quality of life.
  • TransCode's RNA therapy targets microRNA-10b, a unique biomarker of metastasis, using an innovative approach to treat advanced cancers.

Impact - Why it Matters

This development matters because it represents a targeted approach to treating metastatic cancer, one of the most challenging aspects of oncology. Colorectal cancer is among the leading causes of cancer deaths worldwide, and recurrence after initial treatment remains a significant problem. By focusing on patients with circulating tumor DNA—a marker of minimal residual disease—this trial addresses the critical window when cancer might be returning but hasn't yet formed detectable tumors. The RNA-based approach targeting microRNA-10b offers a novel mechanism against metastasis that could potentially benefit not just colorectal cancer patients but those with other cancers expressing this biomarker. Successful development could lead to new treatment options for patients who currently have limited alternatives after standard therapies fail, potentially improving survival rates and quality of life for those facing advanced cancers.

Summary

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments, has taken a significant step forward in its cancer research by submitting an Investigational New Drug (IND) application amendment to the U.S. Food and Drug Administration. This submission paves the way for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, which will be conducted by Quantum Leap Healthcare Collaborative within the innovative PRE-I-SPY program. The trial, expected to begin in the first half of 2026, will enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA (ctDNA), a critical marker associated with minimal residual disease (MRD) and cancer recurrence. Under the leadership of Dr. Paula Pohlmann of MD Anderson Cancer Center, this dose-expansion study represents a targeted approach to addressing metastatic cancer by focusing on tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis.

TransCode Therapeutics' portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells, positioning the company at the forefront of RNA-based cancer treatments. The announcement was distributed through BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and life sciences sectors. BioMedWire provides comprehensive corporate communications solutions, including access to wire solutions via InvestorWire, article syndication to thousands of outlets, enhanced press release distribution, and social media distribution to millions of followers. This platform ensures that breaking news and insightful content about companies like TransCode Therapeutics reach a wide audience of investors, journalists, and the general public, cutting through today's information overload to deliver unparalleled recognition and brand awareness.

For investors and stakeholders seeking the latest updates on RNAZ, the company maintains a dedicated newsroom at https://ibn.fm/RNAZ, while additional information about TransCode Therapeutics can be found at www.transcodetherapeutics.com. The full press release detailing this clinical trial advancement is available at https://ibn.fm/9Fw8K, offering deeper insights into this promising development in cancer therapeutics. BioMedWire's role in disseminating this news highlights the importance of specialized communication channels in the rapidly evolving biotech landscape, where timely and accurate information can significantly impact investment decisions and public awareness of medical breakthroughs.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Submits IND Amendment for Phase 2a Cancer Trial Targeting Metastasis

blockchain registration record for this content.